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ABSTRACT 
Fourier Transform Infrared Spectroscopy (FTIR) has been largely employed by scientific researchers to 
improve diagnosis and treatment of cancer, using various biofluids and tissues. The technology has 
proved to be easy to use, rapid and cost-effective for analysis on human blood serum to discriminate 
between cancer versus healthy control samples. The high sensitivity and specificity achievable during 
samples classification aided by machine learning algorithms, offers an opportunity to transform cancer 
referral pathways, as it has been demonstrated in a unique and recent prospective clinical validation 
study on brain tumours. We herein highlight the importance of early detection in cancer research 
using FTIR, discussing the technique, the suitability of serum for analysis and previous studies, with 
special focus on pre-clinical factors and clinical translation requirements and development. 
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ABSTRACT 
Fourier Transform Infrared Spectroscopy (FTIR) has been largely employed by scientific researchers to improve 
diagnosis and treatment of cancer, using various biofluids and tissues. The technology has proved to be easy to 
use, rapid and cost-effective for analysis on human blood serum to discriminate between cancer versus healthy 
control samples. The high sensitivity and specificity achievable during samples classification aided by machine 
learning algorithms, offers an opportunity to transform cancer referral pathways, as it has been demonstrated 
in a unique and recent prospective clinical validation study on brain tumours. We herein highlight the 
importance of early detection in cancer research using FTIR, discussing the technique, the suitability of serum 
for analysis and previous studies, with special focus on pre-clinical factors and clinical translation requirements 
and development. 
1. Introduction 
1.1 Early Diagnosis of Cancer 
Cancer is a significant and growing global health burden. It is the leading cause of mortality in 
people aged younger than 70 years old in 48 countries, and the second leading cause in another 43 
countries, according to the estimates of premature deaths from the World Health Organization (WHO) 
in 2015 [1]. Cancer incidence and mortality are rapidly growing worldwide, as consequence of 
population ageing and growth; the increasing rates reflect also the changes in cancer prevalence and 
distribution of important risk factors for cancer, such as diet and smoking [1]. In 2018, an estimated 
9.6 million people died of cancer worldwide, predicted to rise to 13.0 million by 2030 [2]. In the 
twenty-first century, cancer is forecast to overtake ischaemic heart disease as the leading cause of 
mortality, and be the most significant obstacle to increase life expectancy [1,3]. 
Early diagnosis of cancer is a key strategy to reduce mortality rates, as earlier treatment is more 
effective. Furthermore, continuous progress in molecular biology and cancer development studies has 
resulted in more targeted and effective therapies for many cancers [4].  
Screening is an important strategy for early detection of several cancers and is based on the 
identification of tumour-specific biomarkers, found in multiple biofluids or body tissues. These same 
biomarkers may be used for different purposes, including screening, diagnosis, staging or disease 
monitoring [5].  
The accuracy of screening tests represents the principal factor in the evaluation of clinical utility. 
Sensitivity and specificity are the statistical parameters taken into consideration during such 
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evaluation; the former is related to the ability of the test to identify true positives over false negatives 
and the latter to identify true negatives over false positives [5]. Prostate-Specific Antigen (PSA, 
prostate tumour marker) and other cancer antigen tests such as CA 19-9 (gastrointestinal and 
pancreatic tumour marker) and CA 125 (ovarian tumour marker) are currently used in cancer 
detection. They have high specificity values around and over 90%, however their sensitivity ranges 
from 50-62% (CA 125) [6] to 72% (PSA) [7] and 79-81% (CA 19-9) [8]. When evaluating the efficacy of 
these current biomarkers in cancer screening, their sensitivity and specificity in the context of disease 
prevalence yields a resultant low Positive Predictive Value (PPV). PPV is the likelihood that a positive 
test result predicts a true positive cancer diagnosis; therefore, the use of screening tests with low PPVs 
can lead to over-diagnosis and over-treatment which are both unwarranted and unnecessary [5]. The 
majority of existing cancer biomarkers are unsuitable for use in national or population screening 
programmes, and they are currently used only on an ad-hoc basis in symptomatic individuals. 
Following a screening test, a patient with a positive/abnormal test result will follow a diagnostic 
pathway as shown in Figure 1. This highlights the importance of accurate and effective initial tests as 
a route into clinical investigation and treatment. 
Many different scientific fields and techniques have been explored to improve early detection of 
cancer. Research has focused on identification of circulating tumour DNA (ctDNA), although this is yet 
to effectively penetrate clinical practice, not least because of technical challenges and cost [9]. By 
contrast, infrared (IR) spectroscopy, which can be employed for the analysis of multiple different 
biofluids, has been widely proven by numerous proof-of-principle studies [10–14]. It is low-cost, non-
invasive, rapid, highly sensitive and specific – features that can prove it as a potentially powerful 
clinical tool, which could make early detection possible across many different cancers [15]. 
 
1.2 Infrared Spectroscopy and the Attenuated Total Reflection technique 
Fourier Transform Infrared (FTIR) spectroscopy is a widely utilised analytical technique for the 
spectral characterisation of a wide range of solids, liquids and gases; including both chemical and 
biological species [16,17]. Traditional FTIR spectroscopy involves directly transmitting the infrared 
beam through the sample; however, a more recent and simpler approach involves an Attenuated Total 
Reflection (ATR) mode. This technique measures the changes in infrared radiation from an internally 
reflected beam when contact is made with the sample that is directly placed on top of the ATR crystal 
Figure 1 – Stepwise process of the current cancer detection path in clinical setting. 
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[17]. Experiments with transmission mode showed that resultant spectra are strongly influenced by a 
range of physical phenomena, such as light scattering, refraction and dispersion. As ATR mode 
operates with different optical properties compared to transmission spectroscopy, it overcomes those 
spectral issues [18]. At a certain predetermined angle, the infrared radiation is directed onto a crystal 
with a high refractive index. Within the crystal, there is an internal reflectance which creates an 
evanescent wave that protrudes beyond the surface and into the sample placed on top. The sample 
absorbs energy within the infrared spectrum region dependent on its molecular composition, and 
these absorptions attenuate the IR beam in a detectable way. The attenuated energy beam is then 
passed to the detector by exiting the opposite end of the crystal [17].  
There are two main requirements for the successful spectral acquisition utilising ATR mode: (i) the 
refractive index of the sample must be lower than that of the crystal for internal reflectance to occur, 
and (ii) the evanescent wave only protrudes beyond the crystal 0.5-5 µm therefore the sample must 
be in direct contact with the surface [17]. ATR crystals are available in zinc selenide (ZnSe), zinc 
sulphide (ZnS), germanium (Ge), silicon (Si) and diamond; however, ZnSe, Ge and diamond are the 
most commonly used due to their material properties [19].  Germanium is particularly useful for highly 
absorbing samples, such as rubbers, due to its high refractive index (4.01), however the Ge spectral 
region only ranges from 600-5,000 cm-1. Zinc selenide has a wider spectral region (500-20,000 cm-1), 
however it is only suitable for liquids or soft materials and cannot be used on samples with a pH less 
than 5 or greater than 9. Diamond is universally the preferred material despite the higher initial costs, 
as it has a greater spectral region (10-45,000 cm-1), higher resistance and is chemically inert [19].  
The use and applications of vibrational spectroscopic techniques for biological studies continues 
to increase as it is reproduceable, non-destructive, simple and only requires small amounts of sample 
material [20]. The FTIR peaks can be assigned to specific vibrations of chemical bonds or functional 
groups within the molecule, therefore providing information on the biochemical arrangement [21]; 
Figure 2 shows the typical spectrum of human blood serum analysed with Attenuated Total Reflection 
– Fourier Transform Infrared (ATR-FTIR) spectroscopy and the identifiable biomolecules [22]. Any 
molecular changes associated with disease can be optically probed and detected using FTIR 
spectroscopy as it is sensitive to the full range of biomolecular classes. 
 
Figure 2 – Human blood serum spectrum acquired by ATR-FTIR spectroscopy with relative biomolecules associated to peaks. 
Adapted with permission from ref. [22] 
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1.3 Suitability of Serum 
The majority of research in the biomedical vibrational spectroscopy field have been based on the 
spectroscopic analysis of human tissue, with many pilot studies suggesting it is possible to distinguish 
between healthy and cancerous tissue, as well as benign and malignant tumours [21]. Various 
malignancies - such as breast, lung, colon and prostate tissues - have previously been studied which 
has provided a platform of encouraging results [23–27]. Unfortunately, the technique has yet to make 
a successful transition into routine clinical practice, despite the abundance of promising publications 
[28].  
In the past decade there has been further interest in biofluid spectroscopy [29]. This has been 
mainly due to the ease of sample collection and handling, and minimal preparation required prior to 
spectroscopic analysis [30]. ATR-FTIR spectroscopy is particularly useful for the analysis of biofluids, 
as only minute volumes (µL) of sample are required. With the recent advances in of ATR accessories 
[31] and in complex data analytics [32], high-throughput ATR-FTIR has the potential to deliver a 
patient’s diagnosis within minutes, using a single blood sample. 
Blood components, such as serum and plasma, are commonly analysed in clinical tests, as they 
carry information regarding intra- and extra-cellular events. Blood serum is the liquid part of the blood 
that contains no clotting factors or blood cells [33]. It exists as the most complex biofluid, containing 
over 20,000 different proteins, ranging from the larger abundant proteins like serum albumin 
(50 g L-1) to the smaller protein molecules such as troponin (1 ng L-1) [34]. Blood serum perfuses the 
organs throughout the entire human body, hence it gains proteomes from surrounding tissues and 
cells [35]. The low molecular weight fraction of serum, known as the peptidome, is thought to contain 
cancer-specific diagnostic information, making the spectroscopic biosignature of serum ideal for 
detecting disease states [36].  
Serology is already commonly employed in the clinic, as serum is the preferred specimen for many 
diagnostic tests [37]. The concentrations of various biomarkers and diagnostic indictors can be 
measured in serum samples [38,39]. At present, the levels of biomolecular components such as 
albumin, bilirubin, creatinine and troponin – along with many others, including all the previously 
discussed cancer biomarkers (PSA, CA 19-9 and CA 125) – are all determined using serum tests in the 
health services worldwide.  Therefore, an advantage of using serum for the triage of cancer is the 
potentially smooth transition into current clinical pathways. Since blood serum tests at the primary 
care level are already ordered as standard, the addition of serum spectroscopy into the clinical 
pathway would not significantly disrupt existing practices within the clinic. 
1.4 ATR-FTIR Spectroscopy for Translation to the Clinic 
ATR-FTIR is a promising analytical tool for cancer serum diagnostics for a range of cancers including 
brain [40], lung [41] and ovarian [42], however clinical translation remains elusive. The transition from 
research to routine clinical testing has faced several major technological challenges, as well as the 
challenges presented from the current patient pathway and the clinician acceptance of a new 
diagnostic test. Principally, the IRE is fundamental to spectroscopic interrogation of serum samples 
and must possess a greater refractive index than the biofluid at the analytical interface to facilitate 
production of evanescent waves. As previously mentioned, IREs comprise diamond, germanium or 
zinc selenide substrates, characteristic of high raw material and fabrication costs [31]; these ultimately 
limit the applicability of ATR-FTIR for high-throughput clinical testing. Similarly, the IRE is permanently 
secured to the top-plate of a spectrometer that restricts spectroscopic analysis to a step-wise 
approach where clinical biofluids must be individually spotted, dried, analysed and cleaned, which is 
impractical for high-volume and fast-paced clinical environments. Furthermore, the fixed nature of 
the IRE poses significant biofluid contamination risks, which makes it unsuitable for clinical testing 
where a disposable diagnostic platform is highly desirable. 
5 
 
Recently, the development of micro-fabricated silicon slides for use as IREs has demonstrated 
considerable promise to overcome current practical limitations of ATR-FTIR and facilitate clinical 
translation for cancer diagnostics. In particular, the low-cost, disposable test platform has 
demonstrated the ability to batch process serum samples and diagnose cancer versus non-cancer with 
a sensitivity and specificity of 93.2% and 92.8% respectively in a large, retrospective cohort of 724 
patients [31]. Critical to commercial translation of the proposed diagnostic test has been the careful 
consideration of current challenges in the cancer diagnostic pathway and the best implementation of 
the technology for earlier diagnosis for patients, whilst proving economically viable for health care 
services. To this extent, health economic studies were conducted, showing that the technology would 
be cost-effective as a triage tool in primary or secondary care at test sensitivity and specificity of ≥80% 
[22]. Consequently, the technology recently participated in a prospective clinical validation study at 
the Western General Hospital in Edinburgh (Scotland), where the test performed with sensitivity and 
specificity of 83.3% and 87.0% for the evaluation of symptomatic patients referred to secondary care 
through open access CT to eliminate brain tumour diagnosis [31]. Hence, ATR-FTIR represents a low-
cost screening method for symptomatic patients in primary care, thereby streamlining the current 
imaging diagnostic pathway with substantial cost-saving implications for health services. Furthermore, 
the diagnostic platform highlights the clinical steps required before adoption of novel technologies 
can be considered, and the importance for emerging technologies to integrate and compliment 
current clinical pathways to facilitate future clinical translation of ATR-FTIR within health care settings. 
2. Infrared Spectroscopic Analysis of Biofluids: Modern Attempt at Cancer Detection 
Vibrational spectroscopy affords the opportunity to investigate the molecular composition of 
organic and inorganic compounds. However, only in the recent years, it has seen an increasing interest 
in the numerous potential applications of vibrational spectroscopy, particularly in the clinical 
environment. Although the gold standard for cancer diagnosis remains histology, many studies 
investigated the use of infrared (IR) spectroscopy through the analysis of cells, tissues and biofluids, 
as the simplicity, rapidity and cost-effectiveness of the technique may represent a step forward to 
translation into the clinic and early detection of cancer [43,44]. 
We discuss here the most relevant proof-of-concept studies of the last decade investigating cancer 
detection using high-throughput (HT-) and ATR-FTIR spectroscopy to analyse different biofluids, 
particularly human blood serum. 
In 2010, Backhaus et al. [45] were one of the first to analyse serum with FTIR spectroscopy in 2010, 
in order to detect breast cancer. 98 patients aged 31-96 years old with carcinomas in situ ranging from 
2mm to 2cm in diameter were recruited, along with 98 healthy controls. They analysed 1 µL of serum 
for each patient, after diluting it with 3 µL of distilled water and drying it on a Si-plate. Subsequently, 
the spectra collected were separated into classes using two independent machine learning 
classification methods: cluster analysis (unsupervised) and artificial neural networks (ANN; 
supervised). Both models performed with sensitivity and specificity above 95%. Sensitivity and 
specificity of cluster analysis accounted for 98% and 95% respectively, whilst a sensitivity of 92% and 
a specificity of 100% were determined with ANN. The results were also tested against 11 other 
different diseases separately to confirm no other factors were interfering in the classification models 
and 79% of breast cancer patients were successfully assigned to the correct class. 
Ollesch et al. [46] investigated the use of HT-FTIR transmission spectroscopy to distinguish 
between urinary bladder cancer and suspected bladder cancer patients suffering from inflammation. 
The aim of their research was to identify the spectral biomarkers responsible for the classification and 
validate them through the study. 135 were the patients included in the dataset: 89 urinary bladder 
cancer cases and 46 controls, all confirmed by cytology and pathological biopsy. Both linear 
discriminant analysis (LDA) and random forest (RF) were used as classification models; the latter 
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performed better, scoring high in sensitivity (93±10%) but poorly in specificity (46±18%); results being 
attributable to the class imbalance. In 2014, the research team updated their results by presenting 
multiple data analysis outputs on different datasets, the wider one of 286 patients in total (urinary 
bladder cancer versus control patients). RF classification outperformed the previous specificity values 
obtained, accounting for 86±9%, however the sensitivity dropped of more than ten percentage points 
to 82±9% [47].  
Maitra et al. [48] studied the potential discrimination between four different classes of 
oesophageal diseases: inflammation, Barrett’s, low-grade dysplasia, high-grade dysplasia and 
oesophageal adenocarcinoma. They analysed plasma, saliva, urine and serum; the genetic algorithms 
combined with quadratic discriminant analysis (GA-QDA) model achieved a remarkable performance 
with the serum dataset, scoring only four classification errors in the training set and two in the 
validation set on a total of 124 samples; this showed a powerful use of the ATR-FTIR technique for 
oesophageal cancer discrimination. Moreover, Yap et al. [49] investigated extracellular vesicles 
contained in urine as potential biomarker for prostate cancer detection. Preliminary results of a 
principal component analysis combined with linear discriminant analysis (PCA-LDA) model performed 
on a small dataset (11 patients) showed a potential development of the ATR-FTIR spectroscopy 
diagnostic approach for prostate cancer, as the model achieved a sensitivity of 83% and a specificity 
of 60%. In contrast, Giamougiannis et al. [50] analysed ascetic fluids (i.e. abnormal secretion of fluid 
in the peritoneal cavity) of 45 patients with benign gynaecological pathologies, borderline ovarian 
tumours and confirmed ovarian cancer. The team performed partial least squares discriminant 
analysis (PLS-DA) on the spectral dataset, obtaining 79% sensitivity and 93% specificity of the model 
discriminating cancer samples against benign pathologies and the borderline category; a different data 
analysis approach compared to the ovarian cancer study published in 2013 by Gajjar et al. [42], where 
the best classification rate (95±8%; i.e. average of sensitivity and specificity percentages) to 
individuate ovarian cancer by serum ATR-FTIR analysis was achieved by combining forward feature 
selection (FFS) and the k-nearest neighbours (k-NN) classifier. 
Notwithstanding the potential of the analysis of serum with FTIR spectroscopy for the clinical 
environment, none of these studies have progressed beyond the proof-of-concept stage. However, 
the aforementioned prospective clinical validation study from Butler et al. [31] was recently presented 
with promising results for the detection of brain tumour. Out of 104 patients referred from their GP 
for medical imaging, 12 patients had brain tumours: four glioblastoma multiforme (GBM), three 
anaplastic astrocytoma, two oligoastrocytoma and a medullo-blastoma, an ependymoma and a 
gliosarcoma. The ATR-FTIR spectra acquired from the prospective group of patients were used to 
predict the diagnosis. The support vector machine (SVM) classification model was trained with a 
retrospective cohort of 724 samples. Sensitivity and specificity of the predicted diagnosis of blind data 
accounted for 83.3% and 87.0% respectively, whilst 93.2% and 92.8% were the outputs related to the 
retrospective cohort. This study represents the step towards the translation into the clinical 
environment, having started from a proof-of-principle study in 2014 based on 97 patients [51] and 
subsequently upgraded to a cohort of 433 patients in 2016, achieving 92.8% of sensitivity and 91.5% 
of specificity in an optimised RF classification model [40]. An integration of the ATR-FTIR serum 
analysis into the clinic proposed by Butler et al. [31] is showed in Figure 3. 
Given the difficulties of diagnosis through imaging, brain tissue biopsies remain the only definitive 
way to diagnose brain cancer. The risks associated with a brain tumour biopsy include stroke and 
death, and although the overall risk is small (less than 2%) [52], a non-invasive alternative is highly 
desirable. Further to the early detection of brain tumours at the primary care stage, Cameron et al. 
[53] have recently evidenced the potential to differentiate between brain tumour types. In this study, 
41 lymphoma and 71 GBM serum samples were analysed with ATR-FTIR spectroscopy. The resultant 
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Figure 3 – Proposed integration of a blood test for the triage of brain cancer. Reproduced from ref. [31] (CC by 4.0) 
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spectra were then analysed with three classification models: RF, PLS-DA and SVM; PLS-DA gave the 
best outcomes in terms of specificity and sensitivity, at 90.1% and 86.3% respectively. 
It is clear that the utility of FTIR spectroscopy in the clinical environment, implemented with 
machine learning algorithms, could be an extremely valuable option in cancer research to obtain an 
early diagnosis and discover novel tumour biomarkers. A triage tool consisting in human blood serum 
analysis with ATR-FTIR spectroscopy, set in primary care, would help GPs in their ‘decision to refer’ 
process by providing a comprehensive biochemical panel indicating the likely presence of tumours. 
ATR-FTIR spectroscopy of serum is a promising, rapid, simple, non-invasive, sensitive, specific and cost-
effective cancer diagnosis system [15,31,43]. 
3. Pre-clinical Considerations 
One of the significant benefits of ATR-FTIR spectroscopy as a diagnostic platform is that the 
technique is reagent free, and therefore does not require extensive sample preparation steps that 
may otherwise introduce variation into the data. In overview, the sample preparation for serum 
spectroscopy can be considered as follows: (i) sample collection, (ii) sample storage, (iii) sample 
deposition, and finally, (iv) sample drying. At each of these steps, however, there is still the possibility 
of introducing unwanted variance, and understanding these variances is key to developing a 
consistent and stable diagnostic tool. These pre-clinical considerations have been addressed in the 
developing literature in the field [54].  
Blood collection is a routine process that is largely standardised in clinical practice and research; 
however, small deviations to collection protocols can have an impact on each sample, and therefore 
the quality of spectral data [33]. For blood plasma collection, a number of anticoagulants – including 
heparin and EDTA – are used in clinical practise in order to prevent blood clotting. It has been shown 
that the choice of anticoagulant is noticeable in the resultant infrared spectrum, which may conceal 
underlying biological information [55,56]. Whilst the use of serum may overcome this collection issue, 
other factors (e.g. diet) can also influence the spectral response; however, it is possible to 
quantitatively monitor the relative levels of dietary components such as glucose, lipids, and even 
alcohol, using ATR-FTIR spectroscopy and thus, general variance of these factors in the population 
may need to be considered in cancer diagnostics [57–59].  
Sample storage is critical with regards to spectral quality as well as logistically fitting into the 
potential cancer pathway. Typically, serum samples are allowed to clot, before being temporarily 
refrigerated at 4°C or frozen at -80°C for later use and long-term storage. The use of frozen samples is 
often unavoidable for retrospective clinical studies, but it has been suggested that freezing may be 
beneficial for uptake into the clinical pathway, as sample analysis is then less time dependent [31]. 
Lovergne et al. presented that the largest spectral change in blood components was apparent 
between fresh and frozen samples, whereas subsequent freeze-thaw cycles had no further spectral 
impact [56]. This information would suggest that working with frozen samples can be beneficial to 
sample processing, as well as sample stability. Further studies by these authors have also illustrated 
that long term storage of samples does not have significant impact on spectral output [54,60].  
Inherent to the analysis of blood products by ATR-FTIR spectroscopy is the IRE. In much of the 
literature, the sample is often deposited on the top surface of the IRE, allowing the evanescent wave 
to penetrate through the dried, or wet, sample [10]. Other studies have also employed alternative 
substrates for samples, in order to overcome potential technical and throughput barriers to diagnostic 
applications [31,61,62]. For both approaches, the method of sample deposition can be highly variable 
between operators due to differences in pipetting accuracy that can impact sample volume and 
spread, as well as positional accuracy [56]. A recent study observed that serum deposition upon novel 
IREs was wildly variable between trained and untrained users and that this could be observed 
spectrally [54].  
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Due to the strong IR absorption of water, serum samples are often analysed in the dried state to 
avoid masking of the fingerprint region by water signals. Whilst liquid serum analysis is possible, more 
spectral information is visible in dried serum samples [63,64]. Due to the complex composition of 
blood serum, drying patterns are prominent within dried serum spots, with the coffee ring effect 
commonly observed as a confounding factor in transmission and transflection FTIR spectroscopy 
studies [15, 16]. The large sampling area employed in the ATR modality of FTIR spectroscopy, 
determined by the IRE surface area, helps to overcome spectral variance that can arise from these 
patterns due macro-measurements of the entire serum spot; however, controlled drying conditions 
have been shown to improve spectral reproducibility [54,60,65]. The drying environment is crucial to 
serum drop homogeneity, with humidity, temperature and air flow having significant impact on 
macromolecule spread in the serum drop, as well as crack features, which are known to cause spectra 
distortions in all modalities of FTIR spectroscopy [65]. It is clear that sample deposition and drying are 
therefore closely linked; for instance, serum volume can impact the drying profile of biofluids. 
4. Clinical Translation: Requirements and Developments of Clinical Trials 
The ultimate goal for laboratory-based research is the translation to the clinic; however, 
surprisingly few technologies make this transition [66]. The field of biomedical spectroscopy, including 
ATR-FTIR spectroscopy, has developed considerably in the last two decades yet viable clinical products 
are only just beginning to emerge [67]. Key barriers to translation include disruption to clinical 
workflows and increased economic burden on healthcare providers; despite the clinical benefits that 
new technologies may offer [15]. 
Generally speaking, defining the clinical question is the first step in translational research and 
should tackle an unmet need in the treatment, diagnosis or another specific aspect of a disease or 
clinical problem. The unmet need should be fully explored; for example, in diagnostic applications, the 
diagnostic pathway should be carefully mapped in order to deduce the underlying issues that need to 
be resolved [68]. For the early detection of brain cancer, this process was overviewed in a health 
economic assessment that characterised the current patient pathway and furthermore reported the 
cost implications of a more efficient pathway [22]. A key aspect of this clinical research is the close 
interaction with clinicians, key opinion leaders and stakeholders, whose involvement is paramount to 
defining the clinical utility of any new technologies [15]. 
Coupling this clinical question to an appropriate technique or technology is the next consideration. 
This may require technical developments or adaptations in order to best suit the clinical question, with 
automation a desirable feature of any new technology [69]. For translation ATR-FTIR spectroscopy, 
novel point-of-care technologies including handheld and microfluidic devices have been discussed, as 
well as alternative IRE configurations for batch processing [28,31,70]. 
Proof-of-concept studies are essential evidence of the utility of any new approach to a clinical 
question and will begin to define the potential benefit that can be bought to the clinical pathway. As 
previously discussed, a wealth of proof-of-concept studies have been already completed. For cancer 
diagnostics, often the first step is a binary classification of disease versus non-diseased patients, with 
samples usually obtained from retrospectively stored biobanks. Sample numbers are often a limiting 
factor in the development of new technologies, and a noticeable pattern in the literature is an 
alarming low number of patient numbers used to establish early utility. The use of machine learning 
approaches often employed to classify between patients is heavily influenced by the number of 
patients fed into the training and testing of these computational models [71]. Whilst these studies are 
useful at identifying potential use, often performance indicators are not reflective of true clinical 
performance. It has been suggested that sample sizes in the range of 75-100 samples per class may 
be sufficient to establish good, but not perfect, classifiers at the proof-of-concept stage [72]. More 
complex studies can be defined by observing other samples classes, such as expanding from binary 
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cancer versus non-cancer questions, to further stratification with other diseases and disease sub-
types, such as prostate cancer grading [27]. 
Determining the true clinical utility may only be possible through studies conducted in the 
targeted clinical environment and patient cohort. Clinical feasibility studies, or diagnostic accuracy 
studies, may be required in order to ascertain the diagnostic performance of new tests and 
technologies. The performance can be measured depending on the type of study, with cancer 
diagnostics often measured in terms of sensitivity and specificity; the ability to either accurately detect 
patients with disease or those without, respectively. Although, it is important to note that other 
performance characteristics may be important to clinical utility based on specific questions (e.g. 
population screening), as disease prevalence can have a significant impact on positive and negative 
predictive values, as well as sample numbers required for powered clinical studies. Such trials are 
required for any downstream regulatory process, in which new technologies will require clear trial 
design and documented validation throughout the process. A crucial point in spectroscopic cancer 
diagnostics is that any tests or devices that require regulatory approval will need to be standardised 
and used throughout any pivotal clinical studies, including any machine learning approaches. 
Prospective clinical trials can be costly, but also provide the highest level of evidence.  
In addition to scientific and clinical development, there is also the commercial element; 
intellectual property (IP), funding and international markets can often represent a further barrier to 
translation.  
5. Conclusions 
Early detection of cancer is vital for improving of survival rates and quality of life. A simple, rapid, 
cost-effective, sensitive and specific test is needed in the clinical environment to achieve early 
detection, avoid overtreating and over-diagnosing patients, and to reduce morbidity and mortality. 
ATR-FTIR analysis of biofluids, particularly serum, has been seen to represent an important tool in 
cancer research thanks to the impressive statistical results obtained with different machine learning 
algorithms. However, despite the numerous promising proof-of-concept studies performed in the last 
decades, clinical translation has yet to be achieved. A prospective clinical validation study on brain 
tumours has been recently published [31], carrying hopes and expectations for the clinical 
spectroscopy community. 
Notwithstanding the continuous improvements in cancer research, thanks to the developments 
of instrumentation and analytical methods, the success of clinical translation cannot be confined to 
the scientific world; it also need to be considered under the commercial view. Intellectual property 
matters, difficulties in obtaining funding and competition on international markets often represent 
barriers for proof-of-concept studies, making the ultimate goal difficult to be achieved. 
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